Mineralys Therapeutics, Inc. - Common Stock (MLYS)

Historical Holders from Q1 2023 to Q3 2025

Symbol
MLYS on Nasdaq
CUSIP
603170101
Type / Class
Equity / Common Stock
Shares outstanding
77.4M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
79.3M
Holdings value
$3.01B
% of all portfolios
0.016%
Grand Portfolio weight change
+0.001%
Number of holders
189
Number of buys
108
Number of sells
-76
Average Value change %
0%
Average buys %
+0.003%
Average sells %
-0.006%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mineralys Therapeutics, Inc. - Common Stock (MLYS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Catalys Pacific Fund, LP 13.5% $137M 8.98M Catalys Pacific Fund, LP Jun 30, 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $119M $23M 7.8M +24% RA Capital Management, L.P. Sep 4, 2025
Samsara BioCapital, L.P. 8.2% -10% $96.6M $9.28M 6.35M +10.6% Srinivas Akkaraju Sep 4, 2025
Andera Partners 4.2% $42.1M 2.77M Andera Partners Jun 30, 2025
ADAMS STREET PARTNERS LLC 2.3% $14.5M 1.13M Adams Street Partners, LLC Dec 31, 2024

Institutional Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 79.3M $3.01B +$505M $37.92 189
2025 Q2 65.7M $889M +$52.6M $13.53 164
2025 Q1 61.2M $971M +$245M $15.88 148
2024 Q4 46.5M $572M +$24.8M $12.31 108
2024 Q3 44.4M $540M +$2.38M $12.11 105
2024 Q2 44.2M $517M +$24.2M $11.70 93
2024 Q1 41.9M $541M +$94.1M $12.91 91
2023 Q4 20.5K $176K -$105K $8.60 1
2023 Q3 26.5M $252M -$9.25M $9.51 77
2023 Q2 25.2M $429M +$10.8M $17.05 68
2023 Q1 24.6M $385M +$385M $15.66 66